Triptans are presently a milestone in the treatment of migraine patients. Because of their effectiveness and safety, they have radically improved migraine treatment but their use has meant a substantial increase in spending for medicines. We compared available pharmaceutical forms, pack sizes, indications and dosages of triptans as listed in the summary of product characteristics of eight countries. We found that several differences exist between countries in the presentations of the triptans and in their licensing.
Discrepancies between Europena countries and USA and Canada in the availability of triptans and their licensed clinical properties / G., Stirparo; F., Palazzo; S., DE FILIPPIS; Martelletti, Paolo. - In: THE JOURNAL OF HEADACHE AND PAIN. - ISSN 1129-2369. - 4:(2003), pp. S88-S90. [10.1007/s101940300019]
Discrepancies between Europena countries and USA and Canada in the availability of triptans and their licensed clinical properties.
MARTELLETTI, Paolo
2003
Abstract
Triptans are presently a milestone in the treatment of migraine patients. Because of their effectiveness and safety, they have radically improved migraine treatment but their use has meant a substantial increase in spending for medicines. We compared available pharmaceutical forms, pack sizes, indications and dosages of triptans as listed in the summary of product characteristics of eight countries. We found that several differences exist between countries in the presentations of the triptans and in their licensing.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
